Big Tech and pharmaceutical companies are accelerating the implementation of artificial intelligence in the healthcare ...

Merck has not shied away from splashy takeovers in the past. In 2015, the company agreed to buy U.S. lab equipment supplier ...

These are the kinds of stocks long-term investors will often be interested in, since they must have excellent, resilient ...

As SpringWorks Therapeutics nears a key regulatory decision in the U.S., the Connecticut-based cancer and rare disease ...

Germany's Merck KGaA said it is in advanced talks for a potential acquisition of SpringWorks Therapeutics, a U.S. biopharmaceutical company that specializes in rare diseases and cancer.

The Institute of Chemical Technology, Mumbai, in collaboration with the Mumbai Biocluster, successfully hosted the 5th Annual ...

Guggenheim maintained a Buy rating on Merck (NYSE:MRK) shares but reduced the price target to $115 from $122. The adjustment follows a comprehensive review of the pharmaceutical giant's fourth-quarter ...

Welcome to Fierce Pharma's regulatory tracker ... where it's being marketed by Merck’s regional commercial partner Zhifei Biological Products. Rob David previously called the expansion to ...

TD Cowen made a significant adjustment to its stance on Merck (NSE:PROR) shares, downgrading the pharmaceutical giant from "Buy" to "Hold". Accompanying the downgrade, the firm also revised its price ...

As the Q4 2024 pharma earnings period rolls on through the first month of President Donald Trump’s second term, executives ...

On the particularly thorny issue of retaining his stake in the financial outcome of a lawsuit pending against Merck Pharmaceuticals over its product Gardasil, the secretary-designate said ...